Anika Therapeutics Inc. (ANIK)
-NasdaqGS 14.40 
0.25(1.77%) May 17, 4:00PM EDT
| Prev Close: | 14.15 |
|---|
| Open: | 14.18 |
|---|
| Bid: | 11.01 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 19.50 |
|---|
| Beta: | 1.67 |
|---|
| Next Earnings Date: | 30-Jul-13 |
|---|
| Day's Range: | 14.07 - 14.46 |
|---|
| 52wk Range: | 9.13 - 16.29 |
|---|
| Volume: | 64,714 |
|---|
| Avg Vol (3m): | 94,749 |
|---|
| Market Cap: | 194.49M |
|---|
| P/E (ttm): | 16.20 |
|---|
| EPS (ttm): | 0.89 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- Pediatric Approval for MDCO/BMY's RecothromZacks(Wed, May 15)
- Amgen to Set Up JV in ChinaZacks(Tue, May 14)
- ANIKA THERAPEUTICS INC FinancialsEDGAR Online Financials(Sat, May 11)
- Disappointing 1Q Earnings for IARTZacks(Fri, May 10)
- Wider-than-Expected Loss at DynavaxZacks(Tue, May 7)
- ANIKA THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 6)
- Anika Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- Anika Therapeutics Earnings Call scheduled for 9:00 am ET todayCCBN(Thu, May 2)
- ANIKA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExEDGAR Online(Wed, May 1)
- Anika Therapeutics Reports First-Quarter 2013 Financial ResultsBusiness Wire(Wed, May 1)
- Q1 2013 Anika Therapeutics Earnings Release - After Market CloseCCBN(Wed, May 1)
- Anika Therapeutics Announces Date of First-Quarter 2013 Financial Results Conference CallBusiness Wire(Fri, Apr 5)
- 5 Stocks Ready to Break Outat TheStreet(Fri, Mar 22)
- Anika heads to arbritation over Merogel injectableat bizjournals.com(Fri, Mar 15)
Key Statistics
| Forward P/E (1 yr): | 11.90 |
|---|
| P/S (ttm): | 2.65 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.28 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | 0.44 |
|---|
Business Summary
Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair.
View More